Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Our News
Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.
GoldCoast has completed a brokered private placement raising $5.8 million, meeting a key condition for its proposed amalgamation with Psyence.
Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.
Psyence Group Inc. has entered into an Amending Agreement with GoldCoast Resource Corp. to revise the previously announced November 2025 Amalgamation Agreement.
Psyence Group’s RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana’s Shallow Continental Shelf
Psyence Group Inc. (CSE: PSYG) has announced that its proposed reverse takeover target, GoldCoast Resource Corp., has been granted ten contiguous offshore reconnaissance licenses by Ghana’s Minerals Commission. Covering roughly 10,000 square kilometres along Ghana’s western offshore continental shelf, the licenses allow GoldCoast to begin early-stage reconnaissance work under Ghanaian mining regulations, with an initial 12-month term and renewal options. Psyence and GoldCoast also confirmed they are continuing to progress their proposed transaction, which remains subject to customary regulatory, technical disclosure, financial, shareholder, and Canadian Securities Exchange approval requirements.